Vor Biopharma Inc.
VOR- Exchange
- Nasdaq
- Industry
- Biological Products, (No Diagnostic Substances)
- SEC CIK
- 0001817229
In the last 90 days, Vor Biopharma Inc. insiders filed 0 open-market purchases and 1 sale; 102 institutions reported holding it in 13F filings for Q2 2026, worth $893.0M in total; no superinvestor holds it.
13F holders, Q2 2026
Institutional positions in Vor Biopharma Inc. as of Jun 30, 2026. Investment managers with $100 million or more in US stocks report their long positions on Form 13F within 45 days after each quarter ends. How 13F works
- Institutional holders
- 102
- +22 vs. Q1 2026
- Shares held
- 48.5M
- +8.06M (+19.9%) vs. Q1 2026
- Total value
- $893.0M
- +$176.2M (+24.6%) vs. Q1 2026
- New holders
- 39
- 35 more added
- Sold out
- 17
- 19 more reduced
Compare with Q1 2026: new holders, sold out and not filed yet
Holders and value by quarter
Institutions reporting VOR on Form 13F each quarter since Q1 2021, and the total value they reported. Values are as of each quarter end, so they also move with the share price.
| Quarter | Holders | Value |
|---|---|---|
| Q2 2026 | 102 | $893.0M |
| Q1 2026 | 80 | $716.9M |
| Q4 2025 | 55 | $332.0M |
| Q3 2025 | 37 | $183.4M |
| Q2 2025 | 35 | $91.9M |
| Q1 2025 | 46 | $43.2M |
| Q4 2024 | 52 | $67.6M |
| Q3 2024 | 54 | $33.5M |
| Q2 2024 | 71 | $54.5M |
| Q1 2024 | 69 | $139.7M |
| Q4 2023 | 60 | $134.1M |
| Q3 2023 | 59 | $127.7M |
| Q2 2023 | 71 | $187.8M |
| Q1 2023 | 60 | $325.7M |
| Q4 2022 | 58 | $400.3M |
| Q3 2022 | 48 | $125.5M |
| Q2 2022 | 49 | $154.8M |
| Q1 2022 | 58 | $187.9M |
| Q4 2021 | 61 | $362.0M |
| Q3 2021 | 55 | $481.2M |
| Q2 2021 | 51 | $571.2M |
| Q1 2021 | 49 | $1.31B |
Institutions, Q2 2026
Shares, value and share of portfolio for each institution holding Vor Biopharma Inc.; share changes are against Q1 2026.
| Institution | Shares | Value | % of portfolio | Change in shares | Action |
|---|---|---|---|---|---|
| FMR LLC | 4,932,149 | $90.8M | 0.00% | +3,392,479+220.3% | Added |
| TCG Crossover Management, LLC | 5,673,078 | $104.4M | 2.51% | 00.0% | Unchanged |
| Laurion Capital Management LP | 0 | $0 | 0.00% | −318,670−100.0% | Sold out |
| Propel Bio Management, LLC | 0 | $0 | 0.00% | −314,543−100.0% | Sold out |
| Quadrature Capital Ltd | 0 | $0 | 0.00% | −76,630−100.0% | Sold out |
| Jane Street Group, LLC | 0 | $0 | 0.00% | −75,890−100.0% | Sold out |
| Simplify Asset Management Inc. | 0 | $0 | 0.00% | −53,510−100.0% | Sold out |
| Brevan Howard Capital Management LP | 0 | $0 | 0.00% | −42,217−100.0% | Sold out |
| Irenic Capital Management LP | 0 | $0 | 0.00% | −32,663−100.0% | Sold out |
| Bollard Group LLC | 0 | $0 | 0.00% | −23,987−100.0% | Sold out |
| Axq Capital, LP | 0 | $0 | 0.00% | −15,019−100.0% | Sold out |
| Independent Financial Group, LLC | 0 | $0 | 0.00% | −13,975−100.0% | Sold out |
| Winton Group Ltd | 0 | $0 | 0.00% | −11,870−100.0% | Sold out |
| Cannon Global Investment Management, LLC | 0 | $0 | 0.00% | −11,700−100.0% | Sold out |
| Diametric Capital, LP | 0 | $0 | 0.00% | −10,070−100.0% | Sold out |
| Quantbot Technologies LP | 0 | $0 | 0.00% | −307−100.0% | Sold out |
| MAI Capital Management | 0 | $0 | 0.00% | −40−100.0% | Sold out |
| Ameritas Advisory Services, LLC | 0 | $0 | 0.00% | −37−100.0% | Sold out |
| Fortitude Family Office, LLC | 0 | $0 | 0.00% | −31−100.0% | Sold out |